Baxter’s BioScience business applies a unique combination of expertise in medical devices, pharmaceuticals, and biotechnology to create products that improve patient care worldwide.
Baxter is investigating uses within its immunoglobulin portfolio in neurology and immunology, for disorders such as Alzheimer’s disease and multifocal motor neuropathy (MMN).
Baxter’s BioScience business, in conjunction with Halozyme Therapeutics, is investigating developing new delivery technology for subcutaneous administration of IGIV.
Baxter is a fully integrated business that complies with regulatory requirements to ensure product safety, efficacy, and quality. This helps assure high quality products from the plasma donors to patients who benefit from our therapies.
The Baxter Global Pathogen Safety Group is an established leader regarding the safety of plasma-derived therapeutics. The group is dedicated and focused on reducing the risk to Baxter products from current and emerging pathogens.
Baxter has a cutting edge biologics manufacturing expertise in plasma fractionation, recombinant protein production, and proprietary Vero cell vaccine production technology. Baxter’s plasma fractionation facilities strive to increase efficiency and support greater product yields, to ensure that more patients have access to its therapies. The company’s experience in plasma fractionation has also resulted in the development of reliable and innovative therapies for the treatment of various chronic conditions.
While immunoglobulin products have been used to treat primary immunodeficiency (PI) patients for decades, the antibody titers needed to protect PI against certain pathogens are still ill defined. Infrequent virus infections that still occur in PI despite IGIV substitution therapy suggest that a better understanding of the functional antiviral efficacy, ie, the virus neutralization capacity, of specific IGIV lots might be beneficial, particularly given the lack of conventional therapeutic alternatives for the treatment of virus infections.
A better understanding of the functional antibody repertoire of individual IGIV lots may allow for more
Baxter BioScience Grants Program
For more information on subcutaneous injection, please click here to view the video.
